BHCM
BCRX icon

Brevan Howard Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Brevan Howard Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$966K Buy
96,574
+77,686
+411% +$702K 0.01% 1078
2026
Q1 		$180K Buy
+18,888
New +$147K ﹤0.01% 1926
2025
Q4 		– Sell
-325,795
Closed -$2.47M – 1807
2025
Q3 		$2.47M Buy
325,795
+187,491
+136% +$1.56M 0.01% 467
2025
Q2 		$1.24M Buy
138,304
+84,282
+156% +$785K 0.01% 962
2025
Q1 		$405K Sell
54,022
-2,622
-5% -$21.1K ﹤0.01% 774
2024
Q4 		$426K Sell
56,644
-22,824
-29% -$173K ﹤0.01% 664
2024
Q3 		$604K Sell
79,468
-14,999
-16% -$114K ﹤0.01% 631
2024
Q2 		$584K Buy
94,467
+81,968
+656% +$452K 0.01% 553
2024
Q1 		$63.5K Sell
12,499
-57,592
-82% -$324K ﹤0.01% 928
2023
Q4 		$420K Buy
+70,091
New +$406K 0.01% 564

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Brevan Howard Capital Management's BCRX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 411% in Q2 2026, buying an estimated $702K and bringing the position to 96,574 shares worth $966K. The position accounts for 0.01% of the portfolio, ranked #1078.

Brevan Howard Capital Management first reported a position in BCRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.47M in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Brevan Howard Capital Management held 96,574 shares of BioCryst Pharmaceuticals worth $966K as of Q2 2026.
  • Brevan Howard Capital Management bought 77,686 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $702K.
  • BioCryst Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1078 holding.
  • Brevan Howard Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Brevan Howard Capital Management's BioCryst Pharmaceuticals position peaked at $2.47M in Q3 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.